PMC

a COVID-19 vaccine hesitancy and acceptance. b COVID-19 vaccine hesitancy and acceptance if recommended by employer or one’s doctor. a, b COVID-19 acceptance in June 2020 was defined as willingness to take vaccine if proven safe and effective. COVID-19 vaccine acceptance in June 2021 was defined as having received at least one dose of a COVID-19 vaccine and if not, willingness to take the COVID-19 vaccine when it is available to them. Vaccine hesitancy was defined as having reported “no” to the question on whether they have received at least one dose of a COVID-19 vaccine and also either unsure/no opinion, somewhat disagree, or strongly disagree to the question on whether they would take a COVID-19 vaccine when available to them. Four countries (Ghana, Kenya, Peru, and Turkey) were not included in the 2020 global survey. c Potential COVID-19 vaccine acceptance if recommended by employer or one’s doctor among those willing to take vaccine when available and those hesitant to vaccinate. c Potential COVID-19 vaccination was defined as willingness to take the COVID-19 vaccine when it is available if recommended by employer or by doctor.

Attitudes toward general vaccines expressed by pregnant persons, by COVID-19 vaccine acceptance* – United States, May to July 2021. *COVID-19 vaccine acceptance was defined as those who had received the vaccine prior to or during pregnancy or planned to receive the vaccine during pregnancy; COVID-19 vaccine delay was defined as those who planned to receive COVID-19 vaccine, but after pregnancy; COVID-19 vaccine hesitancy was defined as those who were uncertain whether they would receive a COVID-19 vaccine; COVID-19 vaccine refusal was defined as those who had no plans to receive COVID-19 vaccine.

Reasons for receiving the COVID-19 vaccine reported by participants that indicated vaccine willingness (A–C) and Reasons for not wanting to receive the COVID-19 vaccine reported by participants that indicated vaccine unwillingness (D–F). (A) Overall reasons for receiving the COVID-19 vaccine. (B) Reasons for receiving the COVID-19 vaccine reported between male and female participants. (C) Reasons for receiving the COVID-19 vaccine reported between participants with less than a Bachelor's degree or a Bachelor's degree or higher. (D) Overall reasons for not wanting to receive the COVID-19 vaccine. (E) Reasons for not wanting to receive the COVID-19 vaccine across sex. (F) Reasons for not wanting to receive the COVID-19 vaccine reported between participants less than a Bachelor's degree or a Bachelor's degree or higher.

COVID-19 vaccine is delayed in a COVID-19 vaccine + OPV schedule—incremental mortality impact, cost-effectiveness, and benefit-cost of adding OPV as a function of delay in COVID-19 vaccine availability. (A) Incremental deaths averted per 1,000 individuals of adding OPV to COVID-19 vaccine only schedule. (B) Incremental cost-effectiveness ratio per averted death of adding OPV to COVID-19 vaccine only schedule. (C) Incremental benefit-cost ratio of adding OPV to COVID-19 vaccine only schedule. The results reflect the scenario in which vaccine coverage for both vaccines are set at 30%. OPV is administered on day t, and the COVID-19 vaccine is administered d days after OPV. The COVID-19 vaccine is assumed to be 74% effective against infections and reducing infectivity, 95% effective against severity, and require 28 days from administration until the it becomes fully effective. e = effectiveness of OPV vaccine against COVID-19.